Tirzepatide layers GIP-receptor targeting onto GLP-1 agonism — improving insulin efficiency and engaging fat tissue directly in energy metabolism. In non-diabetic obesity, that yields ~21% mean weight loss at 15 mg over 72 weeks, a 47% advantage over semaglutide at max tolerated doses (20.2% vs 13.7% head-to-head), and better fat:lean ratios in matched DXA anchors (~75:25 vs ~62:38) — a better explanation for "less hollowed out" claims than any face-specific effect. The advantage is population-dependent: in type 2 diabetes (where GIP can be less responsive) the ratio advantage may narrow to near-identical (~87:13 vs ~86:14), though tirzepatide still wins on absolute fat loss and HbA1c. No long-term data exists above 15 mg weekly — compounded 30/60 mg vials are containers for sub-15 mg dosing, not license to exceed the envelope.

What Tirzepatide Is

A single peptide activating two post-meal hormone receptors: GLP-1 and GIP. One limb quiets appetite and slows gastric emptying; the other improves insulin efficiency and engages fat tissue in burning fuel — letting people eat less while feeling functional, smoothing glucose, and shifting loss toward fat. Once-weekly injection; Mounjaro and Zepbound are the same molecule (different approvals).

How Tirzepatide Works

These are receptor-pharmacology anchors, not clinical occupancy claims. Practically: lower-dose tirzepatide is more GIP-forward; higher doses bring more GLP-1 appetite pressure, gastric slowing, nausea/constipation risk, and modest resting-HR monitoring. Its weaker GLP-1 arm makes the nausea-driving pathway less dominant, while the GIP arm engages fat cells directly via a heat-producing calcium cycle in white fat (SERCA-mediated futile calcium cycling) — a pathway pure GLP-1 agonists can't access (no GLP-1 receptors in adipose).

Weight Loss Results

The curve flattens sharply between 10 and 15 mg — the last 7–28% of effect costs a 50–200% dose increase. About 57% of 15 mg participants reach ≥20% loss, 36% reach ≥25%.

The 75:25 ratio holds across every measured subgroup (sex, age, weight-loss tier) vs semaglutide's ~62:38. Head-to-head (open-label, 72 weeks): tirzepatide 20.2% vs semaglutide 13.7% mean loss; ≥25% loss in 31.6% vs 16.1%. Diabetes: ~13% at 15 mg (vs ~21% in non-diabetic obesity) with HbA1c reductions of 2.0–2.3%; the ratio advantage collapses to ~87:13 (≈semaglutide) — the limitation that drove retatrutide's stronger GIP arm plus glucagon.

Dosing

Once weekly, subcutaneous; label ladder 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, ~4 weeks/step (~5-day half-life, steady state ~4 weeks).

2.5 mg is now a lower-dose track, not just a tolerance step — a 4-week dose-isolated cohort showed −4.7% body weight, −25% fasting insulin, −30% insulin-resistance score, tolerability like 5 mg. Stop-short: 10 mg retains ~93% of the 15 mg effect, 5 mg ~72%; the effective dose is the lowest that keeps weight trending — the 5–10 mg band. Real-world: across 5 cohorts (40,000+ users), 56–74% sit sub-10 mg by the sixth prescription, with 11–13% six-month loss and a modal maintenance dose of 5 mg. Continuation matters (89.5% of continuators held ≥80% of loss vs 14% regain on placebo switch); step-down-to-lower-dose maintenance is reasonable but not yet trial-validated. Microdose (0.5–2 mg): a 26-week diabetes trial tested 1 mg with measurable dose-dependent HbA1c reduction; weight-loss expectations below 5 mg are extrapolated from linear PK and the GIP-forward-at-low-exposure mechanism. 15 mg ceiling is safety, not efficacy — zero prospective data above it; do not exceed.

Side Effects

Primarily GI and dose-dependent; the dual mechanism may mean less nausea but more constipation than pure GLP-1. At 15 mg over 72 weeks: nausea 33%, diarrhea 23%, constipation 17%, vomiting 12%, abdominal pain 10%, dyspepsia 9%. Less common: fatigue (often under-eating/dehydration), hair thinning (rapid loss), injection-site reactions, reflux. Serious but rare: gallbladder problems (1–2%), pancreatitis (<1%), severe GI events (<1%), thyroid contraindication (MTC/MEN2). Resting heart rate rises modestly and dose-dependently (+0.6 bpm at 5 mg, +2.3 at 10 mg, +2.6 at 15 mg vs +0.1 placebo) — monitor with pre-existing tachyarrhythmia. Oral contraceptives: exposure can drop after initiation or dose increase (delayed gastric emptying) — use a non-oral/barrier method through those windows. Management: slow titration, smaller protein-first meals, avoid fatty/fried foods, hydrate, evening dosing; hold or step back rather than forcing through an unresolved reaction.

Tirzepatide vs Semaglutide

In non-diabetic obesity, tirzepatide produces 47% more weight loss and better fat:lean ratios (75:25 vs ~62:38), with a less prominent biliary signal. In T2D it delivers more absolute fat loss and stronger HbA1c, but the ratio advantage disappears.

Where Tirzepatide Is the Evidence-Led Choice

Best for: non-diabetic obesity with a body-composition priority (the cleanest fat:lean split in the class, GIP-driven, subgroup-stable); aggressive weight-loss magnitude (~21% at 15 mg); post-semaglutide plateaus (the GIP arm engages fat tissue directly); and T2D with body-composition concern (more absolute fat loss). Not the evidence-led choice for cardiovascular risk reduction (semaglutide has placebo-beaten major-event data; tirzepatide showed non-inferiority vs dulaglutide), MASH histologic resolution (semaglutide's anchor is stronger, though tirzepatide has positive histologic data), or oral delivery (only oral semaglutide exists). The decision is mechanism-to-goal alignment.